Статті в журналах з теми "Immunocheckpoint"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-38 статей у журналах для дослідження на тему "Immunocheckpoint".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Rizzo, Mimma, Matteo Santoni, and Camillo Porta. "Treatment sequencing strategies in metastatic renal cell carcinoma: A critical interpretation of available data." Journal of Onco-Nephrology 4, no. 3 (August 18, 2020): 153–64. http://dx.doi.org/10.1177/2399369320943609.
Повний текст джерелаSingh, Navdeep, Sandeep Singh Lubana, George Constantinou, and Andrea N. Leaf. "Immunocheckpoint Inhibitor- (Nivolumab-) Associated Hypereosinophilia in Non-Small-Cell Lung Carcinoma." Case Reports in Oncological Medicine 2020 (May 15, 2020): 1–5. http://dx.doi.org/10.1155/2020/7492634.
Повний текст джерелаBorghaei, Hossein. "Emerging evidence of immunocheckpoint inhibitors in non-small cell lung cancer." Annals of Oncology 28 (October 2017): ix20. http://dx.doi.org/10.1093/annonc/mdx552.
Повний текст джерелаCazzato, Gerardo, Eliano Cascardi, Anna Colagrande, Teresa Lettini, Alessandra Filosa, Francesca Arezzo, Carmelo Lupo, et al. "T Cell Immunoglobulin and Mucin Domain 3 (TIM-3) in Cutaneous Melanoma: A Narrative Review." Cancers 15, no. 6 (March 10, 2023): 1697. http://dx.doi.org/10.3390/cancers15061697.
Повний текст джерелаSantoni, Matteo, Daniel Y. C. Heng, Gaetano Aurilio, Andrea Iozzelli, Lucilla Servi, Andrea Fabiani, Massimo Giannini, et al. "Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma." Current Drug Targets 21, no. 4 (March 2, 2020): 416–23. http://dx.doi.org/10.2174/1389450120666191017113051.
Повний текст джерелаMejías, Claudia, and Osmany Guirola. "Pharmacophore model of immunocheckpoint protein PD-L1 by cosolvent molecular dynamics simulations." Journal of Molecular Graphics and Modelling 91 (September 2019): 105–11. http://dx.doi.org/10.1016/j.jmgm.2019.06.001.
Повний текст джерелаEbata, T., T. Shimizu, S. Iizumi, T. Koyama, A. Shimomura, S. Iwasa, S. Kondo, et al. "Prognostic factors of patients received immunocheckpoint inhibitors in oncology phase 1 trials." Annals of Oncology 28 (November 2017): x40. http://dx.doi.org/10.1093/annonc/mdx658.004.
Повний текст джерелаSonmez, Ozlem, Ozlem Nuray Sever, Basak Oyan, and Osman Gokhan Demir. "Immunotherapy releated cardiomyopathy." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e14601-e14601. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e14601.
Повний текст джерелаSaigi, Maria, Juan J. Alburquerque-Bejar, and Montse Sanchez-Cespedes. "Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front." Oncogene 38, no. 31 (June 28, 2019): 5921–32. http://dx.doi.org/10.1038/s41388-019-0855-x.
Повний текст джерелаTakamori, S., T. Komiya, and E. Powell. "P75.06 Survival Benefit From Immunocheckpoint Inhibitors in Stage IV Non-Small Cell Lung Cancer Patients With Brain Metastases." Journal of Thoracic Oncology 16, no. 3 (March 2021): S575—S576. http://dx.doi.org/10.1016/j.jtho.2021.01.1040.
Повний текст джерелаZheng, Aixian, Yanlin Du, Yiru Wang, Youshi Zheng, Zhaoyu Ning, Ming Wu, Cuilin Zhang, Da Zhang, Jingfeng Liu, and Xiaolong Liu. "CD16/PD-L1 bi-specific aptamer for cancer immunotherapy through recruiting NK cells and acting as immunocheckpoint blockade." Molecular Therapy - Nucleic Acids 27 (March 2022): 998–1009. http://dx.doi.org/10.1016/j.omtn.2022.01.010.
Повний текст джерелаTuca, Albert, Rosa Gallego, Ismael Ghanem, Mireia Gil-Raga, and Jaime Feliu. "Chemotherapy and Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer." Journal of Clinical Medicine 9, no. 12 (December 11, 2020): 4015. http://dx.doi.org/10.3390/jcm9124015.
Повний текст джерелаGambini, Donatella, Stefano Ferrero, and Elisabetta Kuhn. "Lynch Syndrome: From Carcinogenesis to Prevention Interventions." Cancers 14, no. 17 (August 24, 2022): 4102. http://dx.doi.org/10.3390/cancers14174102.
Повний текст джерелаTessema, Belay, Andreas Boldt, Brigitte König, Melanie Maier, and Ulrich Sack. "Flow-Cytometry Intracellular Detection and Quantification of HIV1 p24 Antigen and Immunocheckpoint Molecules in T Cells among HIV/AIDS Patients." HIV/AIDS - Research and Palliative Care Volume 14 (August 2022): 365–79. http://dx.doi.org/10.2147/hiv.s374369.
Повний текст джерелаTakamori, S., T. Komiya, and E. Powell. "MA15.07 Survival Benefit From Immunocheckpoint Inhibitors in Stage IV Non-small Cell Lung Cancer Patients ≥75 Years Old of Age." Journal of Thoracic Oncology 16, no. 10 (October 2021): S936. http://dx.doi.org/10.1016/j.jtho.2021.08.193.
Повний текст джерелаLiu, Jinhui, Xing Chen, Yi Jiang, and Wenjun Cheng. "Development of an immune gene prognostic classifier for survival prediction and respond to immunocheckpoint inhibitor therapy/chemotherapy in endometrial cancer." International Immunopharmacology 86 (September 2020): 106735. http://dx.doi.org/10.1016/j.intimp.2020.106735.
Повний текст джерелаMa, Xiaoting, Yujian Zhang, Shan Wang, and Jing Yu. "Predictive value of tumor mutation burden (TMB) with targeted next-generation sequencing in immunocheckpoint inhibitors for non-small cell lung cancer (NSCLC)." Journal of Cancer 12, no. 2 (2021): 584–94. http://dx.doi.org/10.7150/jca.48105.
Повний текст джерелаKakizaki, Masatoshi, Yuichiro Yamamoto, Motoyuki Otsuka, Kouichi Kitamura, Masatoshi Ito, Hideki Derek Kawai, Masamichi Muramatsu, Tatehiro Kagawa, and Ai Kotani. "Extracellular vesicles secreted by HBV-infected cells modulate HBV persistence in hydrodynamic HBV transfection mouse model." Journal of Biological Chemistry 295, no. 35 (July 10, 2020): 12449–60. http://dx.doi.org/10.1074/jbc.ra120.014317.
Повний текст джерелаZhang, Geng, Yi Xu, Sen Zhang, and Huifang Zhou. "The ICOSL Expression Predicts Better Prognosis for Nasopharyngeal Carcinoma via Enhancing Oncoimmunity." BioMed Research International 2020 (January 9, 2020): 1–9. http://dx.doi.org/10.1155/2020/9756732.
Повний текст джерелаHuang, Wan-Ting, Chee Ho Chew, Amanda Chen, Kang-Yuan Lee, Hsing-Lun Lee, Po-Hao Feng, Jeng-Fong Chiou, Kuan-Chou Lin, Po-Li Wei, and Chien-Chung Chen. "Abstract 200: Microtube Array Membrane-Hollow Fiber Assay (MTAM-HFA): A combination of immunocheckpoint blocker (ICBs) and secondary drug anti-cancer drug screening system with significant clinical value propositions for personalized medicine and pre-clinical drug development." Cancer Research 82, no. 12_Supplement (June 15, 2022): 200. http://dx.doi.org/10.1158/1538-7445.am2022-200.
Повний текст джерелаSalabert, Laura, Marine Gross-Goupil, Thibaud Haaser, Jean-Christophe Bernhard, Jean Palussière, and Alain Ravaud. "Impact of metastatic local treatment in the strategy of metastatic renal cell carinoma including sterotactic radiotherapy, surgery, and radiofrequency in an expert center." Journal of Clinical Oncology 36, no. 6_suppl (February 20, 2018): 596. http://dx.doi.org/10.1200/jco.2018.36.6_suppl.596.
Повний текст джерелаZhou, Chengzhi, Zhanhong Xie, Yinyin Qin, Laiyu Liu, Hua Zhang, Weineng Feng, Xiaohong Xie, et al. "Genomic profiling of pulmonary lymphoepithelioma-like carcinoma (PLELC)." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 1572. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.1572.
Повний текст джерелаMassari, Francesco, Matteo Santoni, Chiara Ciccarese, and Daniele Santini. "The immunocheckpoints in modern oncology: the next 15 years." Expert Opinion on Biological Therapy 15, no. 7 (June 10, 2015): 917–21. http://dx.doi.org/10.1517/14712598.2015.1035251.
Повний текст джерелаNdembe, Gloriana, Mirko Marabese, Ilenia Intini, Alessandra Fabbri, Massimo Moro, Mario Occhipinti, Elisa Sottotetti, Giuseppe Lo Russo, Monica Ganzinelli, and Massimo Broggini. "Abstract 2380: The effect of metabolic alterations on chemo-immunotherapy response in non-small-cell lung cancer model." Cancer Research 82, no. 12_Supplement (June 15, 2022): 2380. http://dx.doi.org/10.1158/1538-7445.am2022-2380.
Повний текст джерелаLi, Lincheng, Zhaoda Deng, Zhaohui Xiao, Wenbo Zou, and Rong Liu. "Analysis of Pyroptosis-Related Signature for Predicting Prognosis and Tumor Immune Microenvironment in Pancreatic Cancer." Frontiers in Oncology 12 (May 31, 2022). http://dx.doi.org/10.3389/fonc.2022.770005.
Повний текст джерелаHu, Meng, Weirong Yao, and Qinglin Shen. "Advances and challenges of immunocheckpoint inhibitors in the treatment of primary liver cancer." Frontiers in Genetics 13 (September 30, 2022). http://dx.doi.org/10.3389/fgene.2022.1005658.
Повний текст джерелаZhang, Yu, Lifeng Wang, Rutian Li, and Baorui Liu. "The emerging development of tumor mutational burden in patients with NSCLC." Future Oncology, February 12, 2020. http://dx.doi.org/10.2217/fon-2019-0650.
Повний текст джерелаBoguszewska-Byczkiewicz, Katarzyna, and Agnieszka Kołacińska-Wow. "Liquid biopsy in targeting gene polymorphism related to the response within immunocheckpoint inhibitors therapeutic regimen." Medical Research Journal, May 10, 2021. http://dx.doi.org/10.5603/mrj.a2021.0022.
Повний текст джерелаZhang, Jun, Yu Xia, Xiaomei Zhou, Honghao Yu, Yufang Tan, Yaying Du, Qi Zhang, and Yiping Wu. "Current landscape of personalized clinical treatments for triple-negative breast cancer." Frontiers in Pharmacology 13 (September 16, 2022). http://dx.doi.org/10.3389/fphar.2022.977660.
Повний текст джерелаWang, Liguo, Song Han, Changxiang Yan, Yakun Yang, Zhiqiang Li, and Zuocheng Yang. "The role of clinical factors and immunocheckpoint molecules in the prognosis of patients with supratentorial extraventricular ependymoma: a single-center retrospective study." Journal of Cancer Research and Clinical Oncology, January 2, 2021. http://dx.doi.org/10.1007/s00432-020-03425-1.
Повний текст джерелаChen, Jierong, Lianghe Lu, Chunhua Qu, Gari A, Fangqi Deng, Muyan Cai, Wei Chen, Lie Zheng, and Jiewei Chen. "Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy." Frontiers in Medicine 9 (September 20, 2022). http://dx.doi.org/10.3389/fmed.2022.981001.
Повний текст джерелаKawashima, Atsunari, Takayuki Kanazawa, Kumiko Goto, Mitsunobu Matsumoto, Yu Ishizuya, Cong Wang, Yoshiyuki Yamamoto, et al. "MP73-02 IMMUNOLOGICAL CLASSIFICATION IN RENAL CELL CARCINOMA BASED ON IMMUNOCHECKPOINT MOLECULES: THE RELATIONSHIP WITH TUMOR AGGRESSIVENESS AND THE PRESENCE OF INTRA-TUMOR DIVERSITY." Journal of Urology 197, no. 4S (April 2017). http://dx.doi.org/10.1016/j.juro.2017.02.3347.
Повний текст джерелаTakamori, Shinkichi, Takefumi Komiya, and Emily Powell. "Survival benefit from immunocheckpoint inhibitors in stage IV non‐small cell lung cancer patients with brain metastases: A National Cancer Database propensity‐matched analysis." Cancer Medicine, December 19, 2020. http://dx.doi.org/10.1002/cam4.3675.
Повний текст джерелаMerino, María, Teresa Lozano, Noelia Casares, Hugo Lana, Iñaki F. Troconiz, Timo L. M. ten Hagen, Grazyna Kochan, Pedro Berraondo, Sara Zalba, and María J. Garrido. "Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model." Journal of Nanobiotechnology 19, no. 1 (April 13, 2021). http://dx.doi.org/10.1186/s12951-021-00846-z.
Повний текст джерелаChiang, Zu-Chian, Shubin Fang, Yang-kun Shen, Dongya Cui, Huanjiao Weng, Dawei Wang, Yuxiang Zhao, Jizhen Lin, and Qi Chen. "Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo." Frontiers in Oncology 12 (May 12, 2022). http://dx.doi.org/10.3389/fonc.2022.857927.
Повний текст джерелаKawashima, Atsunari, Yoshiyuki Yamamoto, Mototaka Sato, Wataru Nakata, Yoichi Kakuta, Yu Ishizuya, Yuichiro Yamaguchi, et al. "FAN score comprising fibrosis-4 index, albumin–bilirubin score and neutrophil–lymphocyte ratio is a prognostic marker of urothelial carcinoma patients treated with pembrolizumab." Scientific Reports 11, no. 1 (October 27, 2021). http://dx.doi.org/10.1038/s41598-021-00509-x.
Повний текст джерелаRoberta, P., U. Isola, M. Marchetti, M. Giusti, F. Manca, and R. Montisci. "P144 PEMBROLIZUMAB–INDUCED MYOCARDITIS." European Heart Journal Supplements 24, Supplement_C (May 1, 2022). http://dx.doi.org/10.1093/eurheartj/suac012.139.
Повний текст джерелаAnnibali, Ombretta, Antonella Bianchi, Alba Grifoni, Valeria Tomarchio, Mariantonietta Tafuri, Martina Verri, Giuseppe Avvisati, and Anna Crescenzi. "A novel scoring system for TIGIT expression in classic Hodgkin lymphoma." Scientific Reports 11, no. 1 (March 29, 2021). http://dx.doi.org/10.1038/s41598-021-86655-8.
Повний текст джерела